**Dear Sir:**

The clinical outcome of stroke differs between sexes, representing the first cause of death in women globally \[[@b1-jos-2019-03223]\]. Studies showing differences in the results of endovascular therapy and thrombectomy according to sex are limited and have not been systematically explored \[[@b2-jos-2019-03223]\]. In fact, those studies have not explored the impact of sex in relation to the speed of accessing reperfusion therapies. Moreover, stroke care differs between community and tertiary hospitals, mainly due to difficult access to health resources. However, sex disparities by type of hospital have not been previously explored.

A prospective and multi-center registry was conducted to explore the clinical results according to the sex of patients with anterior circulation ischemic strokes treated with endovascular treatment (approved by the Institutional Review Board of every participating hospital, internal code 0992-N-17). Moreover, we investigated whether stroke women are attended in a similar way than men in those nine hospitals network referring to our comprehensive stroke center, regarding the type of hospital and the presence or not of stroke units (SUs) with specialized stroke physicians in those referring centers.

Demographic data and clinical characteristics of stroke were registered. We collected data regarding the presence of previous recombinant tissue plasminogen activator (rtPA) administration. Treatment intervals were measured in each phase of the process (door to brain imaging time, door to needle time, computed tomography \[CT\] to needle time, door to arterial puncture time, and puncture to recanalization time).

Angiographic results were measured by the modified Thrombolysis in Cerebral Infarction (mTICI) scale. Recanalization success was defined as mTICI grade 2b-3. Functional outcomes were evaluated with the modified Rankin Scale (mRS) at 90 days.

A total of 492 stroke patients treated using endovascular therapies were included, of which 220 were women. Women were older than men (75±13 years vs. 67±13 years, *P*=0.001). Three hundred twenty-three patients (65.65%) came from hospitals with SU. The complete clinical characteristics according to sex are shown in [Table 1](#t1-jos-2019-03223){ref-type="table"}.

There was no statistical difference in previous rtPA treatment between the groups (41.1% in women vs. 46% in men, *P*=0.281). With regard to treatment intervals, there were differences in door to CT time (49.49±110.61 minutes in women vs. 33.13±52.70 minutes in men, *P*=0.042) and in door to needle time (64.78±45.61 minutes in women vs. 51.76±30.41 minutes in men, *P*=0.022) in patients with previous rtPA administration. Longer delays in treatment administration, especially in women, were found in hospitals without SU ([Figure 1](#f1-jos-2019-03223){ref-type="fig"}).

There were no differences in terms of the successful of recanalization according to sex (88.2% in women vs. 91.0% in men, *P*=0.166). The proportion of patients with mRS score ≤2 at 90 days was lower in women (78.8%) than in men (86.3%) (*P*=0.042). In fact, being a woman increased the odds of having a bad functional outcome (odds ratio \[OR\], 1.66; 95% confidence interval \[CI\], 1 to 2.76; *P*=0.048), however, these differences were lost after age adjustment (OR, 1.2; 95% CI, 0.73 to 2.13; *P*=0.43). Women from hospitals without SU had the lowest rate of independency at 90 days (61.7% in women from hospitals without SU vs. 76.84% in women from hospitals with SU, *P*=0.023). We observed in the univariate analysis that being a woman doubled the odds of becoming dependent at those hospitals (OR, 2.09; 95% CI, 1.09 to 4.03; *P*=0.027), and that was true even after age adjustment (OR, 1.98; 95% CI, 1.02 to 3.84; *P*=0.044). No differences were found in mortality rate by sex (11.7% in women vs. 7.5% in men, *P*=0.103) or by hospital-level.

It is widely accepted that functional outcomes after a stroke are worse in women \[[@b1-jos-2019-03223]\]. Regarding differences in healthcare provision between sexes, our data shows that there are important differences in the management of stroke by sex in our environment, especially in the door to needle time. Previous studies have shown that women are less likely to receive acute treatment \[[@b3-jos-2019-03223]\], but only few studies about sex differences in door to needle times among rtPA-treated patients are available with different results \[[@b4-jos-2019-03223]\].

Our study also showed that community hospitals without specialized care are where the greatest differences exist between men and women in both management and outcomes. Stroke center type contributes to the underutilization of rtPA and also was an important hospital-level predictor of door to needle times in previous studies, with a higher proportion of patients treated within 60 minutes in hospitals with comprehensive stroke centers \[[@b5-jos-2019-03223]\].

One of the underlying reasons for this fact may be that nonspecific symptoms are more common in women, which makes the diagnosis of stroke more difficult to perform, even more in centers without specialists stroke physicians. These delays in women have been published previously but there are no well-designed studies to elucidate the reasons behind that fact \[[@b2-jos-2019-03223]\]. However, whether less attention is paid to women arriving with such symptoms to the emergency department remains a plausible explanation.

As for endovascular treatment variables, no differences were found in puncture to recanalization time and recanalization rates. This fact could reflect that the procedure is automatically performed independently of patient sex. Studies examining sex differences in recanalization or outcomes after endovascular treatment in stroke are lacking. Several secondary analyses of 90-day outcomes according to sex using data from randomized clinical trials \[[@b6-jos-2019-03223]\] and also real-world studies \[[@b3-jos-2019-03223],[@b7-jos-2019-03223],[@b8-jos-2019-03223]\] have been done with different results.

Our data shows that women are likely to have worse prognosis in terms of disability. This difference is even greater in patients from hospitals without SU. In fact, despite the effect of age in women\`s outcome (women are older), in these centers female sex is an independent predictive factor for dependency at 90 days as it remains after age adjustment. Fewer patients attended, the lack of specific protocols and specialized stroke physicians may also contribute to sex differences among these centers.

Our findings showed a disparity in stroke care according to sex, which was larger in hospitals without specialized stroke care. Despite being an observational study, our study shows for the first time that hospital-level has an influence on sex disparities outcomes after endovascular treatment. It also includes the largest number of patients until now, which allow us to conclude that women might have worse results than men after endovascular treatment since they arrive later to those therapies.

Strict adherence to protocols, training, and specialization of care could decrease these differences and improve stroke prognosis among women. This picture of real world will encourage clinicians dealing with this population to develop protocols in those centers where they are lacking in order to improve the care of female patients and remove disparities. In fact, prospective studies designed with specific interventions for this purpose are needed and might be complementary to standard reperfusion therapies.
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Clinical characteristics according to patient sex

  Characteristic                                                                Women (n=220)   Men (n=272)   *P*
  ----------------------------------------------------------------------------- --------------- ------------- ---------
  Age (yr)                                                                      75±13           67±13         0.001
  Medical history                                                                                             
   Atrial fibrillation/flutter                                                  75 (34.1)       62 (22.8)     0.005
   Diabetes mellitus                                                            52 (23.7)       90 (33.1)     0.021
   Hypertension                                                                 167 (75.9)      190 (69.8)    0.134
   Hyperlipidemia                                                               100 (45.5)      127 (46.7)    0.784
   Obesity (BMI \>30 kg/m^2^)                                                   68 (30.9)       62 (22.8)     0.042
   Smoker                                                                       25 (11.4)       82 (30.2)     \<0.001
   Alcohol intake                                                               4 (1.8)         57 (20.9)     \<0.001
   Prior stroke/transient ischemic attack                                       38 (27.3)       48 (17.7)     0.913
   Previous myocardial infarction                                               27 (12.3)       66 (24.3)     0.001
   Peripheral vascular disease                                                  3 (1.4)         22 (8.1)      0.001
   Chronic kidney disease                                                       17 (7.7)        19 (7.0)      0.753
  Medication use at baseline                                                                                  
   Anticoagulants                                                               46 (20.9)       43 (15.8)     0.144
   Aspirin                                                                      64 (29.1)       102 (37.8)    0.043
   Clopidogrel                                                                  17 (7.7)        11 (4.1)      0.083
   Statin                                                                       77 (35.2)       106 (39.1)    0.368
   Angiotensin-converting enzyme inhibitors or angiotensin receptors blockers   80 (36.5)       82 (30.0)     0.127
  Stroke etiology                                                                                             \<0.001
   Atherotrombotic                                                              35 (16.1)       111 (41.7)    
   Cardioembolic                                                                134 (61.7)      103 (38.7)    
   Other                                                                        48 (22.1)       52 (19.5)     
  Pre-stroke center type                                                                                      
   Hospitals with stroke unit                                                   146 (66.3)      177 (65.1)    0.451
  Clinical characteristics at presentation                                                                    
   NIHSS at admission                                                           16±6            15±6          0.067
   Pre-stroke mRS ≤2                                                            204 (92.7)      263 (96.7)    0.047
   SPAN-100 (stroke prognostication using age and NIHSS)                        90.9±15         82.7±15       \<0.001
  Clinical outcomes                                                                                           
   Mortality                                                                    27 (11.7)       21 (7.5)      0.103
   Intracranial hemorrhage                                                      36 (17.8)       34 (14.3)     0.312
   NIHSS post-procedure                                                         13±7            12±8          0.010
   NIHSS at discharge                                                           7±8             6±7           0.133
   mRS ≤2 at 90 days                                                            184 (78.8)      202 (86.3)    0.042

Values are presented as mean±standard deviation or number (%).

BMI, body mass index; NIHSS, National Institute of Health Stroke Score; mRS, modified Rankin Scale.
